HUM-MOLGEN events: Pharmacotoxicology

HUM-MOLGEN -> Events -> Meetings and Conferences

July 26, 2001

SMi conferences, The Hatton, Hatton Gardens, London
29th & 20th October 2001

Day One – Monday 29th October

8.30 Registration & Coffee

9.00 Chairman's Opening Remarks
Dr Gerhard Gross, Head, ADME, Novartis

STREAMLINING THE ASSESSMENT OF PRODUCT SAFETY IN THE CLINICAL DEVELOPMENT SETTING
9.10 New strategies in the drug development process
Dr Ebiere Bolodeoku, Senior Medical Advisor, International Clinical Safety, Europe, Amgen

FUNDAMENTALS OF PHARMACOTOXICOLOGY
9.40 Pre-clinical safety
Dr Johan Gabrielsson, Senior Principal Scientist, AstraZeneca R & D

REDUCING FAILURE RATES
10.20 Early prediction of pharmacokinetics
Dr David Leahy, Director, Cyprotex

11.00 Morning Coffee

FORMULATION CONSIDERATIONS FOR IN VIVO STUDIES
11.20 Safety and evaluation
Dr Luigi G. Martini, Team Leader, Dosage Form Design, GlaxoSmithKline

TOXICOPROTEOMICS USING THE PROTEINCHIP® SYSTEM
12.00 Strategies for discovery and validation of biomarkers in pre-clinical sciences
Dr Huw Davies, UK Program Manager, Ciphergen Biosystems

12.40 Networking Lunch

WHAT IS PREDICTIVE TOXICOLOGY?
2.00 Potential applications of “new” technology
Dr Paul Trennery, Vice President, Worldwide Safety Assessment, GlaxoSmithKline R & D

INTEGRATION OF PROTEOMICS AND PREDICTIVE TOXICOLOGY
2.40 Enhancing the drug discovery and development process
Dr Sandy Kennedy, Director, Pharmacoproteomics & Preclinical Development, Oxford Glycosciences

3.20 Afternoon Tea

UTILISING GENE EXPRESSION PROFILING
3.40 Predictive toxicology using multiple gene expression platforms
Mark Porter, Associate Director, Toxicology Bioinformatics, GeneLogic

TOXIGENOMIC STRATEGIES
4.20 Potential applications and uses
Dr Elizabeth Foot, Pharmacogenetic Scientist, New Product Development, GlaxoSmithKline R & D

5.00 Chairman’s Closing Remarks and Close of Day One

Day Two – Tuesday 30th October

8.30 Re-registration and Coffee

9.00 Chairman's Opening Remarks
Dr John Connelly, Director, Biology, Metabometrix

IN SILICO METHODS FOR TOXICITY AND ADME PREDICTION
9.10 Early ADME/toxicology studies
Dr Anita White, Group Leader, In Silico ADME/Tox, Global Metabolism & Investigative Services, Pharmacia

IMPROVING TOXICOLOGICAL DATA MANAGEMENT
9.40 Case study: Genesis ScreenTM
Dr H. Ralph Snodgrass, President & Chief Executive Officer, VistaGen

COMPUTATIONAL AND DATABASE APPROACHES
10.20 Predicting outcome at the discovery stage
Dr Dale Johnson, Chief Scientific Officer, ddPlatform LLC

11.00 Morning Coffee

IN VITRO BIOAVAILABILITY, METABOLISM & DRUG EVALUATION
11.20 Assessing the pitfalls
Dr Florence Salmon, Head, Kinetics & Metabolism, TNO Pharma

METABOLIC DRUG-DRUG INTERACTIONS
12.00 Drug profiling
Dr Louis Leung, Principal Research Scientist, Drug Metabolism, Wyeth-Ayerst Research

12.40 Networking Lunch

DRUG METABOLISM
2.00 The regulatory perspective
Dr Rae Yuan, Associate Clinical Director, Department of Clinical Pharmacology, F. Hoffman-La Roche

COMPUTER ASSISTED APPROACHES FOR DRUG METABOLISM PREDICTION
2.40 Advantages of an early prediction of drug metabolism
Dr Patrizia Crivori, Scientist, Global Metabolism & Investigative Sciences, Pharmacia

3.20 Afternoon Tea

IMPROVING THE THROUGHPUT OF TOXICITY SCREENING
3.40 Focus on microarray technology
Dr Erik Jongedijk, Director, Business Development, Marketing & Sales, Europe, Phase-1 Molecular Toxicology

METABONOMIC APPROACHES TO SAFETY & EFFICACY ASSESSMENT
4.20 Enabling technology for rapid throughput in vivo toxicity assessment
Dr John Connelly, Director, Biology, Metabometrix

5.00 Chairman's Closing Remarks and Close of Conference

Organized by:

Louise Maher

Invited Speakers:

A unique opportunity to learn from leading industry experts including:
 Dr Paul Trennery, Vice President, Worldwide Safety Assessment, GlaxoSmithKline R & D
 Dr Ebiere Bolodeoku, Senior Medical Advisor, International Clinical Safety, Europe, Amgen
 Dr Rae Yuan, Associate Clinical Director, Department of Clinical Pharmacology, F. Hoffman-La Roche
 Dr Johan Gabrielsson, Senior Principal Scientist, AstraZeneca R & D
 Dr Luigi G. Martini, Team Leader, Dosage Form Design, GlaxoSmithKline
 Dr Anita White, Group Leader, In Silico ADME/Tox, Global Metabolism & Investigative Services, Pharmacia
 Dr Elizabeth Foot, Pharmacogenetic Scientist, New Product Development, GlaxoSmithKline R & D
 Dr Louis Leung, Principal Research Scientist, Drug Metabolism, Wyeth-Ayerst Research
 Dr Patrizia Crivori, Scientist, Global Metabolism & Investigative Sciences, Pharmacia
 Dr Sandy Kennedy, Director, Pharmacoproteomics & Preclinical Development, Oxford Glycosciences
 Dr John Connelly, Director, Biology, Metabometrix
 Mark Porter, Associate Director, Toxicology Bioinformatics, GeneLogic
 Dr Erik Jongedijk, Director, Business Development, Marketing & Sales, Europe, Phase-1 Molecular Toxicology
 Dr H. Ralph Snodgrass, President & Chief Executive Officer, VistaGen
 Dr David Leahy, Director, Cyprotex
 Dr Florence Salmon, Head, Kinetics & Metabolism, TNO Pharma
 Dr Huw Davies, UK Program Manager, Ciphergen Biosystems
 Dr Dale Johnson, Chief Scientific Officer, ddPlatform LLC

Chaired by:
 Dr Gerhard Gross, Head, ADME, Novartis
 Dr John Connelly, Director, Biology, Metabometrix

Deadline for Abstracts:

No abstracts required

Registration:

Fee is £1291

E-mail:

lmaher@smi-online.co.uk

Posted by:

Louise Maher

Host:

213.38.112.46